ЛИПИДСНИЖАЮЩАЯ ТЕРАПИЯ: ОТ ИСТОКОВ В СЕГОДНЯШНИЙ ДЕНЬ

Библиографические ссылки:

Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А. С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 5471https://doi.org/10.15829/1560-4071-2023-5471. EDN YVZOWJ.

Frank L. J. Visseren, François Mach, Yvo M. Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck et al. ESC Scientific Document Group, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021 Sept; 42(34): 3227-3337https://doi.org/10.1093/eurheartj/ehab484

Caggiula A.W., Christakis G., Farrand M., et al. The multiple risk factor intervention trial (MRFIT): IV. Intervention on blood lipids. Preventive Medicine. 1981; 10(4): 443-75https://doi.org/10.1016/0091-7435(81)90060-8

Larsson S.C., Butterworth A.S., Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023 Dec 14; 44(47):4913-4924https://doi.org/10.1093/eurheartj/ehad736. PMID: 37935836; PMCID: PMC10719501.

Bove M., Cicero A.F.G., Borghi C. Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019 Mar; 24(1): 63-69https://doi.org/10.1080/14728214.2019.1591372. Epub 2019 Mar 21. PMID: 30841759.

Ruscica M., Ferri N., Banach M., Sirtori C.R., Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023 Jan 18; 118(17): 3288-3304https://doi.org/10.1093/cvr/cvac020. PMID: 35238338.

Patel K.K., Sehgal V.S., Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. Eur J Pharmacol. 2022 May 5; 922: 174906https://doi.org/10.1016/j.ejphar.2022.174906. Epub 2022 Mar 20. PMID: 35321818; PMCID: PMC9007885.

Virani S.S., Newby L.K., Arnold S.V., et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29; 148(9): e9-e119https://doi.org/10.1161/CIR.0000000000001168

Arvanitis M., Lowenstein C.J. Dyslipidemia. Ann Intern Med. 2023 Jun; 176(6): ITC81-ITC96https://doi.org/10.7326/AITC202306200. Epub 2023 Jun 13. PMID: 37307585.

Joshi K. Ayurveda biology – the road not trodden. J Ayurveda Integr Med. 2023 Mar-Apr; 14(2): 100726https://doi.org/10.1016/j.jaim.2023.100726. PMID: 37263724; PMCID: PMC10307822.

Thottapillil A., Kouser S., Kukkupuni S.K., et al. An 'Ayurveda-Biology' platform for integrative diabetes management. J Ethnopharmacol. 2021 Mar 25; 268: 113575https://doi.org/10.1016/j.jep.2020.113575. Epub 2020 Nov 9. PMID: 33181283.

Attardo S., Musumeci O., Velardo D., Toscano A. Statins Neuromuscular Adverse Effects. Int J Mol Sci. 2022 Jul 28; 23(15): 8364https://doi.org/10.3390/ijms23158364. PMID: 35955495; PMCID: PMC9369175.

Howard J.P., Wood F.A., Finegold J.A., Nowbar A.N., Thompson D.M., Arnold A.D., Rajkumar C.A., Connolly S., Cegla J., Stride C., Sever P., Norton C., Thom S.A.M., Shun-Shin M.J., Francis D.P. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021 Sep 21; 78(12): 1210-1222https://doi.org/10.1016/j.jacc.2021.07.022. PMID: 34531021; PMCID: PMC8453640.

Pergolizzi J.V. Jr., Coluzzi F., Colucci R.D., Olsson H., LeQuang J.A., Al-Saadi J., Magnusson P. Statins and muscle pain. Expert Rev Clin Pharmacol. 2020 Mar; 13(3): 299-310https://doi.org/10.1080/17512433.2020.1734451. Epub 2020 Feb 27. PMID: 32089020.

Haxhi J., Thompson P.D. Rationale for the use of metformin and exercise to counteract statin-associated side effects. Int J Clin Pract. 2021 May; 75(5): e13900https://doi.org/10.1111/ijcp.13900. Epub 2020 Dec 20. PMID: 33277775.

Makhmudova U., Lütjohann D., Schulze P.C., Davis H.R., Weingärtner O. Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 Feb 1; 79(4): e151-e152https://doi.org/10.1016/j.jacc.2021.10.047. PMID: 35086663.

Lamb Y.N. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2020 Aug; 20(4): 381-392https://doi.org/10.1007/s40256-020-00421-1. PMID: 32648167.

Kim B.K., Hong S.J., Lee Y. et al. RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022 Jul 30; 400(10349): 380-390https://doi.org/10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18. PMID: 35863366.

Chilbert M.R., VanDuyn D., Salah S., Clark C.M., Ma Q. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Drug Des Devel Ther. 2022 Jul 7; 16: 2177-2186https://doi.org/10.2147/DDDT.S332352. PMID: 35832642; PMCID: PMC9273150.

Ouchi Y., Sasaki J., Arai H., Yokote K., Harada K., Katayama Y., Urabe T., Uchida Y., Hayashi M., Yokota N., Nishida H., Otonari T., Arai T., Sakuma I., Sakabe K., Yamamoto M., Kobayashi T., Oikawa S., Yamashita S., Rakugi H., Imai T., Tanaka S., Ohashi Y., Kuwabara M., Ito H. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019 Sep 17; 140(12): 992-1003https://doi.org/10.1161/CIRCULATIONAHA.118.039415. Epub 2019 Aug 22. PMID: 31434507.

Gunta S.P., O'Keefe J.H., O'Keefe E.L., Lavie C.J. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. Prog Cardiovasc Dis. 2023 Jul-Aug; 79: 12-18https://doi.org/10.1016/j.pcad.2023.02.007. Epub 2023 Mar 5. PMID: 36871887.

Oyama K., Giugliano R.P., Sabatine M.S., Cannon C.P., Braunwald E. Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 Feb 1; 79(4): e153https://doi.org/10.1016/j.jacc.2021.11.018. PMID: 35086664.

Ежов М.В., Обрезан А.Г., Алиева А.С., Ахмеджанов Н.М. Атеросклеротическая рапсодия. РМЖ. 2023; 4: 33-40. – EDN ETLAQY. [Ezhov M.V., Obrezan A.G., Alieva A.S., Akhmedjanov N.M. Atherosclerotic rhapsody. RMZH. 2023; 4: 33-40. - EDN ETLAQY.]

de Lorgeril M., Salen P., Martin J-L., et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction. Circulation. 1999; 99(6): 779-85https://doi.org/10.1161/01.cir.99.6.779

Cupido A.J., Reeskamp L.F., Hingorani A.D., Finan C., Asselbergs F.W., Hovingh G.K., Schmidt A.F. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study. JAMA Cardiol. 2022 Sep 1; 7(9): 955-964https://doi.org/10.1001/jamacardio.2022.2333. PMID: 35921096; PMCID: PMC9350849.

Nicholls S.J., Ray K.K., Nelson A.J., Kastelein J.J.P. Can we revive CETP-inhibitors for the prevention of cardiovascular disease? Curr Opin Lipidol. 2022 Dec 1; 33(6): 319-325https://doi.org/10.1097/MOL.0000000000000854. Epub 2022 Oct 21. PMID: 36345867.

Xue H., Zhang M, Liu J, Wang J, Ren G. Structure-based mechanism and inhibition of cholesteryl ester transfer protein. Curr Atheroscler Rep. 2023 Apr; 25(4): 155-166https://doi.org/10.1007/s11883-023-01087-1. Epub 2023 Mar 7. PMID: 36881278; PMCID: PMC10027838.

Banerjee S., De A. Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update. Drug Discov Today. 2021 Jul; 26(7): 1759-1764https://doi.org/10.1016/j.drudis.2021.03.016. Epub 2021 Mar 27. PMID: 33781947.

Metzinger M.P., Saldanha S., Gulati J., Patel K.V., El-Ghazali A., Deodhar S., Joshi P.H., Ayers C., Rohatgi A. Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. J Am Heart Assoc. 2020 Dec 15; 9(24): e018136https://doi.org/10.1161/JAHA.120.018136. Epub 2020 Dec 2. PMID: 33263263; PMCID: PMC7955402.

Nicholls S.J., Nelson A.J. CETP Inhibitors: Should We Continue to Pursue This Pathway? Curr Atheroscler Rep. 2022 Dec; 24(12): 915-923https://doi.org/10.1007/s11883-022-01070-2. Epub 2022 Nov 21. PMID: 36409446.

Tybjærg-Hansen A., Nordestgaard L.T., Christoffersen M. Pharmacogenetics-guided CETP inhibition: an open question? Eur Heart J. 2022 Oct 14; 43(39): 3957-3959https://doi.org/10.1093/eurheartj/ehac398. PMID: 35924304.

Bayer V. An Overview of Monoclonal Antibodies. Semin Oncol Nurs. 2019 Oct; 35(5): 150927https://doi.org/10.1016/j.soncn.2019.08.006. Epub 2019 Sep 2. PMID: 31488319.

Le Basle Y., Chennell P., Tokhadze N., Astier A., Sautou V. Physicochemical Stability of Monoclonal Antibodies: A Review. J Pharm Sci. 2020 Jan; 109(1): 169-190https://doi.org/10.1016/j.xphs.2019.08.009. Epub 2019 Aug 26. PMID: 31465737.

Castelli M.S., McGonigle P., Hornby P.J. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019 Dec; 7(6): e00535https://doi.org/10.1002/prp2.535. PMID: 31859459; PMCID: PMC6923804.

Barale C., Melchionda E., Morotti A., Russo I. PCSK9 Biology and Its Role in Atherothrombosis. Int J Mol Sci. 2021 May 30; 22(11): 5880https://doi.org/10.3390/ijms22115880. PMID: 34070931; PMCID: PMC8198903.

Raal F.J., Kallend D., Ray K.K., Turner T., Koenig W., Wright R.S., Wijngaard P.L.J., Curcio D., Jaros M.J., Leiter L.A., Kastelein J.J.P. ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16; 382(16): 1520-1530https://doi.org/10.1056/NEJMoa1913805. Epub 2020 Mar 18. PMID: 32197277.

Sun Y., Mu G., Xue Z., Wang S., Li X., Han M. Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma. Neuro Oncol. 2023 Nov 2; 25(11): 2100-2102https://doi.org/10.1093/neuonc/noad145. PMID: 37623320; PMCID: PMC10628934.

Wang X., Wen D., Chen Y., Ma L., You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovasc Diabetol. 2022 Jun 15; 21(1): 107https://doi.org/10.1186/s12933-022-01542-4. PMID: 35706032; PMCID: PMC9202167.

Gencer B., Mach F. PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. Curr Med Chem. 2022; 29(6): 1016-1026https://doi.org/10.2174/0929867328666210804091003. PMID: 34348606.

Johns D.G., Campeau L.C., Banka P., Bautmans A., Bueters T., Bianchi E., Branca D. et al. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. 2023 Jul 11; 148(2): 144-158https://doi.org/10.1161/CIRCULATIONAHA.122.063372. Epub 2023 May 1. PMID: 37125593; PMCID: PMC10325562.

Banerjee Y., Pantea Stoian A., Cicero A.F.G., Fogacci F., Nikolic D., Sachinidis A., Rizvi A.A., Janez A., Rizzo M. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1): 9-20https://doi.org/10.1080/14740338.2022.1988568. Epub 2021 Oct 14. PMID: 34596005.

Räber L., Ueki Y., Otsuka T., Losdat S., Häner J.D., Lonborg J., Fahrni G., Iglesias J.F., van Geuns R.J., Ondracek A.S., Radu Juul Jensen M.D., Zanchin C., Stortecky S., Spirk D., Siontis G.C.M., Saleh L., Matter C.M., Daemen J., Mach F., Heg D., Windecker S., Engstrøm T., Lang I.M., Koskinas K.C.; PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10; 327(18): 1771-1781https://doi.org/10.1001/jama.2022.5218. PMID: 35368058; PMCID: PMC8978048.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006. Alirocumab. 2023 Nov 15. PMID: 29999811.

Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S., Faiella-Tommasino J., Forman D.E., Goldberg R., Heidenreich P.A., Hlatky M.A., Jones D.W., Lloyd-Jones D., Lopez-Pajares N., Ndumele C.E., Orringer C.E., Peralta C.A., Saseen J.J., Smith S.C. Jr., Sperling L., Virani S.S., Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18; 139(25): e1082-e1143https://doi.org/10.1161/CIR.0000000000000625.

Gaba P., O'Donoghue M.L., Park J.G., Wiviott S.D., Atar D., Kuder J.F., Im K., Murphy S.A., De Ferrari GM., Gaciong Z.A., Toth K., Gouni-Berthold I., Lopez-Miranda J., Schiele F., Mach F., Flores-Arredondo J.H., López J.A.G., Elliott-Davey M., Wang B., Monsalvo M.L., Abbasi S., Giugliano R.P., Sabatine M.S. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Apr 18; 147(16): 1192-1203https://doi.org/10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13. PMID: 36779348.

Coppinger C., Movahed M.R., Azemawah V., Peyton L., Gregory J., Hashemzadeh M. A Comprehensive Review of PCSK9 Inhibitors. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec; 27: 10742484221100107https://doi.org/10.1177/10742484221100107. PMID: 35593194.

Warden B.A., Duell P.B. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1; 78(2): e157-e174https://doi.org/10.1097/FJC.0000000000001053. PMID: 33990512.

Воевода М.И., Гуревич В.С., Ежов М.В., Сергиенко И.В. Инклисиран – новая эра в гиполипидемической терапии. Кардиология. 2022; 62(6): 57-62https://doi.org/10.18087/cardio.2022.6.n2115

Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019; 380(1): 11-22https://doi.org/10.1056/NEJMoa1812792